Hengrui's oral HRS9531 opens third Phase 3 obesity trial in China
The tablet formulation begins enrolling 675 patients as Hengrui's injectable HRS9531 already runs head-to-head against semaglutide in a separate Phase 3 study.
Executive Summary
- A Phase 3 trial of Hengrui's oral tablet formulation of HRS9531 opened enrollment in China, with its target patient count raised and its completion timeline extended at the same registry update.
- The study will test whether an oral version of HRS9531 can reproduce the weight-loss effect Hengrui already reported for the same drug's earlier tablet formulation, and whether it holds up against the injectable version now running head-to-head against semaglutide.
- This is one of a dozen active or completed HRS9531 trials Hengrui has running across obesity and related metabolic and cardiovascular indications, reflecting a broad formulation and indication strategy rather than a single pivotal bet.
- The trial enters a China and global obesity field dominated by injectable GLP-1 peptides from Eli Lilly and Novo Nordisk, where oral small-molecule GLP-1 receptor programs from multiple sponsors are still working toward Phase 3 data rather than approval.
The trial opens
The study, registered as NCT07670884, moved from Not yet recruiting to Recruiting status on July 21, 2026, according to the trial's ClinicalTrials.gov record. The same registry update raised the anticipated enrollment target from 425 to 675 patients and pushed the primary completion date from July 1, 2027 to October 31, 2027. The trial randomizes participants with a BMI of 28 or higher, or 24 or higher with a weight-related comorbidity, under a quadruple-masked, two-arm design testing HRS9531 tablets against a comparator in China. NCT07670884A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsNCT07670884
What it will measure
The primary endpoint is percentage change from baseline in body weight after 52 weeks of treatment, alongside a co-primary measure of the proportion of patients achieving at least 5% weight loss at the same timepoint. Secondary measures track BMI, waist circumference, blood lipids, blood pressure, glycemic markers, and adverse events through 57 weeks. That endpoint structure mirrors the standard obesity trial design used across the GLP-1 class, built to establish both the magnitude and the durability of weight loss at one year. NCT07670884A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsNCT07670884
Same-drug precedent
Hengrui has already generated human data on an oral formulation of this drug: a completed Phase 2 trial (NCT06841445) of HRS9531 tablets reported Week 26 topline results in June 2026 showing mean weight loss up to 12.1% at the 25 mg and 50 mg doses versus 2.3% for placebo, and the trial met its primary endpoint. That result sets the band this Phase 3 tablet program needs to reproduce at 52 weeks in a larger, longer study. Separately, Hengrui's injectable formulation of HRS9531 is already running a head-to-head Phase 3 trial against semaglutide injection (NCT07285902), a study currently Active, not recruiting with a primary completion date of March 2027.
Operational read
The enrollment target increase and completion-date shift arrived in the same update that moved the trial into active recruiting, a pattern consistent with a sponsor sizing a newly opened study rather than reacting to a shortfall, since enrollment had not yet begun under the prior target. Hengrui has completed all 25 of its prior trials on record with no terminations, and runs 12 active or completed trials of HRS9531 across obesity, obstructive sleep apnea, polycystic ovary syndrome, and heart failure with preserved ejection fraction, indicating an established execution track record on this asset. NCT07670884A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsNCT07670884
Where it sits competitively
The obesity field remains dominated by injectable GLP-1 receptor peptides, led by Eli Lilly's tirzepatide and orforglipron programs and Novo Nordisk's semaglutide and CagriSema trials, both running double-digit numbers of active studies with enrollment in the tens of thousands. Oral small-molecule GLP-1 receptor programs from Structure Therapeutics (aleniglipron), Roche (enicepatide), and AstraZeneca (elecoglipron) are also in Phase 3 testing in obesity, none yet approved in the indication. Hengrui's tablet formulation of HRS9531 enters that same oral, small-molecule sub-field, where no entrant has yet reported Phase 3 results.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.